These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 12174027

  • 21. Steady-state concentrations and dosage of digoxin in relation to kidney function in hospitalized patients over 70 years of age.
    Algotsson A, Sanz E, Alván G.
    J Intern Med; 1991 Mar; 229(3):247-51. PubMed ID: 2007843
    [Abstract] [Full Text] [Related]

  • 22. Can digoxin dose requirements be predicted?
    Dobbs SM, Mawer GE, Rodgers M, Woodcock BG, Lucas SB.
    Br J Clin Pharmacol; 1976 Apr; 3(2):231-7. PubMed ID: 973957
    [Abstract] [Full Text] [Related]

  • 23. Comparison of target concentration intervention strategy with conventional dosing of digoxin.
    Rajendran SD, Rao YM, Thanikachalam S, Muralidharan TR, Anbalagan M.
    Indian Heart J; 2005 Apr; 57(3):265-7. PubMed ID: 16196188
    [Abstract] [Full Text] [Related]

  • 24. Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis.
    Suematsu F, Yukawa E, Yukawa M, Minemoto M, Ohdo S, Higuchi S, Goto Y.
    Eur J Clin Pharmacol; 2001 Apr; 57(1):19-24. PubMed ID: 11372585
    [Abstract] [Full Text] [Related]

  • 25. The effects of captopril on serum digoxin levels in patients with severe congestive heart failure.
    Kirimli O, Kalkan S, Guneri S, Tuncok Y, Akdeniz B, Ozdamar M, Guven H.
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):311-4. PubMed ID: 11471775
    [Abstract] [Full Text] [Related]

  • 26. Population analysis for the optimization of digoxin treatment in Japanese paediatric patients.
    Suematsu F, Minemoto M, Yukawa E, Higuchi S.
    J Clin Pharm Ther; 1999 Jun; 24(3):203-8. PubMed ID: 10438180
    [Abstract] [Full Text] [Related]

  • 27. Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling.
    Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, Mimemoto M.
    Drugs Aging; 2011 Oct 01; 28(10):831-41. PubMed ID: 21970310
    [Abstract] [Full Text] [Related]

  • 28. Individual dosage of digoxin in patients with heart failure.
    Muzzarelli S, Stricker H, Pfister O, Foglia P, Moschovitis G, Mombelli G, Brunner-La Rocca H.
    QJM; 2011 Apr 01; 104(4):309-17. PubMed ID: 21062754
    [Abstract] [Full Text] [Related]

  • 29. Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling.
    Williams PJ, Lane J, Murray W, Mergener MA, Kamigaki M.
    Clin Pharmacokinet; 1992 Jan 01; 22(1):66-74. PubMed ID: 1559308
    [Abstract] [Full Text] [Related]

  • 30. Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals.
    Noormohamed SE, Katseres JK, Stapleton JT.
    Ren Fail; 1998 Jul 01; 20(4):627-33. PubMed ID: 9713882
    [Abstract] [Full Text] [Related]

  • 31. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial.
    Adams KF, Butler J, Patterson JH, Gattis Stough W, Bauman JL, van Veldhuisen DJ, Schwartz TA, Sabbah H, Mackowiak JI, Ventura HO, Ghali JK.
    Eur J Heart Fail; 2016 Aug 01; 18(8):1072-81. PubMed ID: 27492641
    [Abstract] [Full Text] [Related]

  • 32. Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals.
    Hoeschen RJ, Cuddy TE.
    Am J Cardiol; 1975 Apr 01; 35(4):469-72. PubMed ID: 1119396
    [Abstract] [Full Text] [Related]

  • 33. Digoxin serum levels in patients with Chagas' cardiomyopathy and heart failure.
    Ferrari SJ, Bestetti RB, Cardinalli-Neto A, Bortoluzzi TB.
    Rev Soc Bras Med Trop; 2010 Apr 01; 43(5):496-9. PubMed ID: 21085856
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of two prediction models for digoxin dosing.
    Markantonis SL, Kyroudis A, Christopoulos T.
    Pharm World Sci; 1993 Feb 19; 15(1):29-33. PubMed ID: 8485504
    [Abstract] [Full Text] [Related]

  • 35. Update on digoxin therapy in congestive heart failure.
    Haji SA, Movahed A.
    Am Fam Physician; 2000 Jul 15; 62(2):409-16. PubMed ID: 10929703
    [Abstract] [Full Text] [Related]

  • 36. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.
    Yukawa E, Mine H, Higuchi S, Aoyama T.
    J Pharm Pharmacol; 1992 Sep 15; 44(9):761-5. PubMed ID: 1360530
    [Abstract] [Full Text] [Related]

  • 37. Recommended dose of arbekacin, an aminoglycoside against methicillin-resistant Staphylococcus aureus, does not achieve desired serum concentration in critically ill patients with lowered creatinine clearance.
    Fukuoka N, Aibiki M.
    J Clin Pharm Ther; 2008 Oct 15; 33(5):521-7. PubMed ID: 18834367
    [Abstract] [Full Text] [Related]

  • 38. Digoxin may reduce the mortality rates in patients with congestive heart failure.
    Wang L, Song S.
    Med Hypotheses; 2005 Oct 15; 64(1):124-6. PubMed ID: 15533628
    [Abstract] [Full Text] [Related]

  • 39. [Positive ionotropic substances (digitoxin and digoxin). Principles and rules of use].
    Gelu M, Caron J, Libersa C.
    Rev Prat; 1999 May 01; 49(9):1017-23. PubMed ID: 11865453
    [No Abstract] [Full Text] [Related]

  • 40. Therapeutic drug monitoring of digoxin-20 years of experience.
    Grześk G, Stolarek W, Kasprzak M, Krzyżanowski M, Szadujkis-Szadurska K, Wiciński M, Grześk E.
    Pharmacol Rep; 2018 Feb 01; 70(1):184-189. PubMed ID: 29414149
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.